Cellectis S.A SG&A Expenses 2015-2025 | CLLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectis S.A sg&a expenses from 2015 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectis S.A sg&a expenses from 2015 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$213.1B
Amgen (AMGN)	$159.1B
Gilead Sciences (GILD)	$134.7B
Vertex Pharmaceuticals (VRTX)	$117.7B
Bristol Myers Squibb (BMY)	$95B
CSL (CSLLY)	$81.2B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$58.9B
Alnylam Pharmaceuticals (ALNY)	$41.8B
Argenex SE (ARGX)	$34.6B
BioNTech SE (BNTX)	$26.2B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13B
Exelixis (EXEL)	$12.1B
Moderna (MRNA)	$12B
BioMarin Pharmaceutical (BMRN)	$10.8B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.3B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.8B